Flu Shot May Be Less Effective in Those With Lupus
... But the study, published in the August issue of Arthritis & rheumatism , also found that the activity of those T-cells key to immunization were ... E.J. Mundell SOURCE: Arthritis & rheumatism , news release, July 30, 2009 ...Biomarker Could Predict Severe Osteoarthritis
... The study, which appears in the August issue of Arthritis & rheumatism , is the first to establish a laboratory biomarker for the risk of severe ... -- Robert Preidt SOURCE: Arthritis & rheumatism , news release, July 30, 2009 ...Rheumatoid Arthritis Drugs Raise Shingles Risk
... with cancer. In the latest study, researchers from the German rheumatism Research Centre in Berlin looked at 5,040 people taking the TNF blockers ... White, Temple, Texas; Anja Strangfeld, M.D., epidemiology unit, German rheumatism Research Centre, Berlin; Feb. 18, 2009, Journal of the American Medical ...Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
... question Dr. Joachim Listing and a team of specialists with the German rheumatism Research Centre in Berlin set out to answer. Featured in the March 2008 issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ), their study ...Gene Linked to Inflammatory Arthritis Also Raises Heart Risks
... CVD. Their report was published in the February issue of Arthritis & rheumatism . They found evidence that implicates HLA-DRB1 genotypes, already ... -- Robert Preidt SOURCE: Arthritis & rheumatism , news release, Jan. 31, 2008 ...Fingers Point to Risk for Arthritic Knees
... or hip osteoarthritis. Writing in the January issue of Arthritis & rheumatism , the researchers analyzed data from more than 2,000 patients on hospital ... Madeline Vann SOURCE: Arthritis & rheumatism . news release, Jan. 2, 2008 ...46 Million Americans Suffer From Arthritis
... were published in two papers in the January issue of Arthritis & rheumatism . Key findings in the report include: By 2030, almost 67 million ... Officer, Arthritis Foundation, Atlanta; January 2008, Arthritis & rheumatism ...New Kidney Disease Can Be Fatal
... are published in the October issue of the journal Arthritis & rheumatism . This is the first study to examine the prevalence of NSF in dialysis ... -- Robert Preidt SOURCE: Arthritis & rheumatism , news release, Sept. 28, 2007 ...RA Drugs Linked to Slight Skin Cancer Risk
... according to the report in the September issue of Arthritis & rheumatism . The heightened risk for skin cancer is very small, Wolfe emphasized. ... Harvard Medical School, Boston; September 2007, Arthritis & rheumatism ...Sunlight May Cause Rash in Autoimmune Disease
... diseases and autoantibodies in women," Miller said in the news release. The study appears in the August issue of the journal Arthritis & rheumatism . More information The U.S. National Library of Medicine has more about myositis . -- Robert Preidt ...Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
... methotrexate, and no drug-drug interactions were observed. In addition, Lexicon will present Phase 1 data for LX2931 at the European League Against rheumatism (EULAR) annual meeting on June 13, 2009. Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate ...NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
... that may increase the rate of serious cardiovascular adverse events. The new results are being presented today at the 2008 European League Against rheumatism (EULAR) Congress in Paris. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide ...Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
... - RDEA594 Data to Be Presented at the 2008 Annual European Congress of Rheumatology Organized by the European League Against rheumatism (EULAR) - - Initiation of Phase 1 Human Study of RDEA594 Planned in Second Half of 2008 - SAN DIEGO, May 19 ...International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
... is interpreted as low (DAS28 moderate (3.2 5.1). DAS28 corresponds to being in remission according to the criteria of the American rheumatism Association (ARA). (3) The EULAR response criteria is based on the individual amount of change in DAS and the DAS value (low, moderate, high ...Gene expression findings a step toward better classification and treatment of juvenile arthritis
... we currently recognize," Dr. Colbert says. In the first of two such NIAMS-supported studies to be published in the July issue of Arthritis & rheumatism , scientists led by Michael Barnes, Ph.D., of Cincinnati Children's Hospital Medical Center used a large data set to compare a number of children ...8 plants from South Africa may hold potential for treating high blood pressure
... Researchers have recorded (1962) that the plant was pounded into formulations and used by native South Africans to relieve stomach ailments, rheumatism and high fevers. Other researchers found (1966) that native South Africans rubbed the leaves of the plant on the head for sinus headaches and used ...New insights into autoimmunity and depression
... at Tel Aviv University set out to induce depressive hallmarks in mice. Their findings, presented in the March 2007 issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ), shed light on the brain pathways of depression in general and in central nervous system ...New genes implicated in rheumatoid arthritis
... of Michigan Medical Center turned to an ideal population: genetically identical, disease-discordant twins. The July issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ) highlights the results of their state-of-the-art genetic analysis. ...Stem cells from muscles can repair cartilage
... develop in various ways, including into cells that lead to the formation of bone. In a study published in the February 2006 issue of Arthritis & rheumatism ( http://www.interscience.wiley.com/journal/arthritis ), researchers designed a study using muscle-derived stem cells (MDSCs) genetically engineered ...Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
... in 2010 -- Announce TRU-015 Phase 2b (15002) rheumatoid arthritis re-treatment data at the annual meetings of the European League Against rheumatism and the American College of Rheumatology (ACR) -- Announce TRU-015 Phase 2b (2203) rheumatoid arthritis trial data by end of Q4 2009 ...European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
... (5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at European League Against rheumatism Annual Meeting; Jun 2008, Paris, France. (6) Leventhal, LJ. Management of Fibromyalgia. Annals of Internal Medicine. 1999; 131: 850-858. (7) ...Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
... HGS and GSK under a co-development and commercialization agreement entered into in August 2006. At the 2008 Congress of the European League Against rheumatism (EULAR) in June, the Company presented three-year data from a long-term Phase 2 continuation trial demonstrating that belimumab was associated ...Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
... is a member of the American College of Rheumatology and Spanish Society for Rheumatology and has collaborated with the European League Against rheumatism (EULAR) Task Force for Gout and with the Outcome Measures for Rheumatic Arthritis Clinical Trials (OMERACT) group for chronic gout. He serves on the ...Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
... MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an ...Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
... of Synvisc-One six months after the first injection. Data from the study were presented earlier this year at the European League Against rheumatism annual meeting in Barcelona, Spain and have been accepted for a podium presentation at the American Association of Orthopaedic Surgeons annual ...